Topologically inferring pathway activity toward precise cancer classification via integrating genomic and metabolomic data: Prostate cancer as a case

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Liu, Wei ^a   Bai, Xuefeng ^b   Liu, Yuejuan ^b   Wang, Wei ^a   Han, Junwei ^b   Wang, Qiuyu ^b   Xu, Yanjun ^b   Zhang, Chunlong ^b   Zhang, Shihua ^c   Li, Xuecang ^b   Ren, Zhonggui ^b   Zhang, Jian ^b   Li, Chunquan ^b  

^a HEILONGJIANG INSTITUTE OF TECHNOLOGY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c ANHUI AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

BIOSYNTHESIS; CLASSIFICATION; DATA BASE; GENETICS; GENOMICS; HUMAN; MALE; METABOLISM; METABOLOMICS; PROGNOSIS; PROSTATE TUMOR; REPRODUCIBILITY; SOFTWARE;

BIOMARKERS, TUMOR; BIOSYNTHETIC PATHWAYS; DATABASES AS TOPIC; GENOMICS; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; PROGNOSIS; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SOFTWARE;

EID: 84939795842     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13192     Document Type: Article

References (55)

1. Perez-Diez, A., Morgun, A., Shulzhenko, N. Microarrays for cancer diagnosis and classification. Adv Exp Med Biol 593, 74-85 (2007).
2. Ein-Dor, L., Zuk, O., Domany, E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci USA 103, 5923-5928 (2006).
3. Koulman, A., Lane, G. A., Harrison, S. J., Volmer, D. A. From differentiating metabolites to biomarkers. Anal Bioanal Chem 394, 663-670 (2009).
4. Ludwig, J. A., Weinstein, J. N. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5, 845-856 (2005).
5. Sreekumar, A. et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914 (2009).
6. Van 't Veer, L. J.et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
7. Dupuy, A., Simon, R. M. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99, 147-157 (2007).
8. Michiels, S., Koscielny, S., Hill, C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365, 488-492 (2005).
9. Barry, M. J. Screening for prostate cancer-the controversy that refuses to die. N Engl J Med 360, 1351-1354 (2009).
10. Li, J. et al. Exploiting the determinants of stochastic gene expression in Saccharomyces cerevisiae for genome-wide prediction of expression noise. Proc Natl Acad Sci USA 107, 10472-10477 (2010).
11. Shalek, A. K. et al. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature 498, 236-240 (2013).
12. Alemu, E. Y., Carl, J. W., Jr., Corrada Bravo, H., Hannenhalli, S. Determinants of expression variability. Nucleic Acids Res 42, 3503-3514 (2014).
13. Guo, Z. et al. Towards precise classification of cancers based on robust gene functional expression profiles. BMC Bioinformatics 6, 58 (2005).
14. Lee, E., Chuang, H. Y., Kim, J. W., Ideker, T., Lee, D. Inferring pathway activity toward precise disease classification. PLoS Comput Biol 4, e1000217 (2008).
15. Su, J., Yoon, B. J., Dougherty, E. R. Accurate and reliable cancer classification based on probabilistic inference of pathway activity. PLoS One 4, e8161 (2009).
16. Kim, S., Kon, M., DeLisi, C. Pathway-based classification of cancer subtypes. Biol Direct 7, 21 (2012).
17. Carter, S. L., Brechbuhler, C. M., Griffin, M., Bond, A. T. Gene co-expression network topology provides a framework for molecular characterization of cellular state. Bioinformatics 20, 2242-2250 (2004).
18. Lu, X., Jain, V. V., Finn, P. W., Perkins, D. L. Hubs in biological interaction networks exhibit low changes in expression in experimental asthma. Mol Syst Biol 3, 98 (2007).
19. Raj, A., van Oudenaarden, A. Nature, nurture, or chance: stochastic gene expression and its consequences. Cell 135, 216-226 (2008).
20. Li, J., Liu, Y., Kim, T., Min, R., Zhang, Z. Gene expression variability within and between human populations and implications toward disease susceptibility. PLoS Comput Biol 6 (2010).
21. Liu, W. et al. Topologically inferring risk-active pathways toward precise cancer classification by directed random walk. Bioinformatics 29, 2169-2177 (2013).
22. Vaske, C. J. et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26, i237-245 (2010).
23. Evers, N. M. et al. Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant. Chem Biol Interact 220, 222-230 (2014).
24. Miller, L. D. et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102, 13550-13555 (2005).
25. Li, H., Xiao, D., Hu, L., He, T. Association of CYP1A1 polymorphisms with prostate cancer risk: an updated meta-analysis. Mol Biol Rep 39, 10273-10284 (2012).
26. Shaik, A. P., Jamil, K., Das, P. CYP1A1 polymorphisms and risk of prostate cancer: a meta-analysis. Urol J 6, 78-86 (2009).
27. Silig, Y. et al. Polymorphisms of CYP1A1, GSTM1, GSTT1, and prostate cancer risk in Turkish population. Cancer Invest 24, 41-45 (2006).
28. Chang, B. L. et al. Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int J Cancer 106, 375-378 (2003).
29. Kojima, S. et al. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer 106, 405-413 (2012).
30. Weiss, T. S. et al. Polyamine levels of human colorectal adenocarcinomas are correlated with tumor stage and grade. Int J Colorectal Dis 17, 381-387 (2002).
31. Linsalata, M. et al. Prognostic value of tissue polyamine levels in human colorectal carcinoma. Anticancer Res 22, 2465-2469 (2002).
32. Soda, K. The mechanisms by which polyamines accelerate tumor spread. J Exp Clin Cancer Res 30, 95 (2011).
33. Phillips, H. S. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157-173 (2006).
34. Nishiyama, T., Hashimoto, Y., Takahashi, K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10, 7121-7126 (2004).
35. Nishiyama, T., Ikarashi, T., Hashimoto, Y., Wako, K., Takahashi, K. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. J Urol 178, 1282-1288; discussion 1288-1289 (2007).
36. Freije, W. A. et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64, 6503-6510 (2004).
37. Pawitan, Y. et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7, R953-964 (2005).
38. Schipper, R. G., Romijn, J. C., Cuijpers, V. M., Verhofstad, A. A. Polyamines and prostatic cancer. Biochem Soc Trans 31, 375-380 (2003).
39. Mostaghel, E. A. Steroid hormone synthetic pathways in prostate cancer. Translational Andrology and Urology 2, 212-227 (2013).
40. Gregory, C. W., Johnson, R. T., Jr., Mohler, J. L., French, F. S., Wilson, E. M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61, 2892-2898 (2001).
41. Mohler, J. L. et al. Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate 51, 247-255 (2002).
42. Evaul, K., Li, R., Papari-Zareei, M., Auchus, R. J., Sharifi, N. 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology 151, 3514-3520 (2010).
43. Kohler, S., Bauer, S., Horn, D., Robinson, P. N. Walking the interactome for prioritization of candidate disease genes. Am J Hum Genet 82, 949-958 (2008).
44. Li, Y., Patra, J. C. Integration of multiple data sources to prioritize candidate genes using discounted rating system. BMC Bioinformatics 11 Suppl 1, S20 (2010).
45. Draghici, S. et al. A systems biology approach for pathway level analysis. Genome Res 17, 1537-1545 (2007).
46. Tusher, V. G., Tibshirani, R., Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98, 5116-5121 (2001).
47. Chuang, H. Y., Lee, E., Liu, Y. T., Lee, D., Ideker, T. Network-based classification of breast cancer metastasis. Mol Syst Biol 3, 140 (2007).
48. Poisson, L. M., Sreekumar, A., Chinnaiyan, A. M., Ghosh, D. Pathway-directed weighted testing procedures for the integrative analysis of gene expression and metabolomic data. Genomics 99, 265-274 (2012).
49. Edgar, R., Domrachev, M., Lash, A. E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30, 207-210 (2002).
50. Varambally, S. et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8, 393-406 (2005).
51. Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
52. Cai, C. et al. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest 123, 1109-1122 (2013).
53. Li, C. et al. SubpathwayMiner: a software package for flexible identification of pathways. Nucleic Acids Res 37, e131 (2009).
54. Lu L., Zhang, Y.-C., Yeung, C. H., Zhou, T. Leaders in Social Networks, the Delicious Case. PLoS One 6, e21202 (2011).
55. Yang, R., Daigle, B. J., Jr., Petzold, L. R., Doyle, F. J., 3rd. Core module biomarker identification with network exploration for breast cancer metastasis. BMC Bioinformatics 13, 12 (2012).